What is the translation of " PACKAGE LEAFLETS " in Slovenian?

• navodila za uporabo
• navodil za uporabo
• navodilih za uporabo

Examples of using Package leaflets in English and their translations into Slovenian

Information on the label and package leaflets;
Informacije na etiketi in priloženih navodilih za uporabo;

Read the package leaflets for these medicines for their dosage and directions on‘how to take' them.
Za odmerjanje in navodila za jemanje teh zdravil preberite ustrezno navodilo za uporabo.

It is very important that you read the package leaflets that are provided with these medicines too.
Zelo pomembno je, da preberete tudi navodila za uporabo, priložena tem zdravilom.

The database shall facilitate the search for information already authorised for package leaflets;
Baza podatkov olajša iskanje podatkov že odobrenih zdravil za navodila za uporabo;

Refer also to the package leaflets of any other medicines that are used in combination with Pegasys.
Glejte tudi navodila za uporabo drugih zdravil, ki jih uporabljate v kombinaciji z zdravilom Pegasys.

In addition the applicant shall provide samples or mock-ups of the packaging, labels and package leaflets for the medicinal product concerned.
Vlagatelj predloži tudi vzorce ali osnutke ovojnine, nalepke in navodila za uporabo za zadevno zdravilo.

Summaries of product characteristics and package leaflets are published in the Centralna baza zdravil(Medicinal products database).
Povzetki glavnih značilnosti zdravil in navodila za uporabo so objavljena v centralni bazi zdravil.

As Comtan tablets will be taken together with other levodopa medicines, please also read the package leaflets of these medicines carefully.
Ker boste tablete Comtan jemali skupaj z drugimi zdravili z levodopo, skrbno preberite tudi njihova navodila za uporabo.

It is very important that you also read the package leaflets for the other antiviral medicines that you take with Exviera.
Pomembno je, da preberete tudi navodila za uporabo drugih protivirusnih zdravil, ki jih jemljete z zdravilom Exviera.

As Entacapone Teva tablets will be taken together with other levodopa medicines, please also read the package leaflets of these medicines carefully.
Ker boste tablete Entakapon Teva jemali skupaj z drugimi zdravili z levodopo, skrbno preberite tudi njihova navodila za uporabo.

In this segment of the paediatric market, comprehensible and transparent package leaflets play a particularly important role in preventing behaviour that could potentially harm the paediatric patient.
V tem segmentu tržišča s področja pediatrije, imajo razumljiva in pregledna navodila za uporabo zdravil pomembno vlogo pri preprečevanju vedenja, ki bi morda lahko škodilo pediatričnemu bolniku.

Pharmacovigilance was a first success, with the adoption of drug safety portals that included the package leaflets and information on the medicines.
Farmakovigilanca je bil prvi uspeh z uvedbo portalov o varnosti zdravil, ki so vključevali navodila za uporabo in informacije o zdravilih.

The marketing of medicinal products whose labelling and package leaflets comply with this Directive should not be prohibited or impeded on grounds connected with the labelling or package leaflet..
(41) Promet z zdravili, katerih označevanje in navodila za uporabo so v skladu s to direktivo, se ne sme prepovedati ali ovirati iz razlogov, povezanih z označevanjem ali navodilom za uporabo..

Since Daklinza must always be used with other medicines against hepatitis C infection, please read the package leaflets for these medicines.
Ker je zdravilo Daklinza treba vedno uporabljati skupaj z drugimi zdravili za zdravljenje okužbe z virusom hepatitisa C, preberite ustrezna navodila za uporabo.

Reminder: Please also read the“Possible side effects” in the Package Leaflets for peginterferon alfa and ribavirin before you start taking Victrelis.
Opozorilo: Preden začnete jemati zdravilo Victrelis, prosimo, preberite tudi poglavje"Možni neželeni učinki" v navodilih za uporabo za peginterferon alfa in ribavirin.

Reminder to adult patients prescribed combination therapy of this medicine, boceprevir and ribavirin: Please read the“Possible side effects” section of these Package Leaflets.
Opozorilo za odrasle bolnike, ki imajo predpisano zdravljenje s tem zdravilom, boceprevirjem in ribavirinom: Prosimo, preberite poglavje"Možni neželeni učinki" v teh navodilih za uporabo.

In Italy, pharmacies are required by law to print out updated package leaflets that the pharmaceutical industry has put on a database.
V Italiji morajo lekarne po zakonu tiskati posodobljena navodila za uporabo, ki jih v zbirko podatkov naloži farmacevtska industrija.

The general public shall have access to information in the product database as regards the list of the authorised veterinary medicinal products, their summaries of product characteristics and package leaflets.
Splošna javnost ima dostop do informacij v zbirki podatkov o zdravilih glede seznama odobrenih zdravil za uporabo v veterinarski medicini, njihovih povzetkov glavnih značilnosti in navodil za uporabo.

Presentation of officially approved information in a different form may be necessary due to the fact that at present officially approved information such as package leaflets and specialised information may sometimes be difficult for patients to understand.
Uradno odobrene informacije je treba predstaviti v drugačni obliki zato, ker so lahko takšne informacije, kot so navodila za uporabo in povzetek glavnih značilnosti zdravila, za bolnike včasih težko razumljive.

Scientific conclusions and grounds for amendment of the summaries of product characteristics and package leaflets presented by the emea overall summary of the scientific evaluation of piroxicam containing medicinal products(see annex i).
Znanstveni zaključki in podlaga za dopolnilo povzetka glavnih značilnosti zdravila in navodila za uporabo, ki jih je predstavila evropska agencija za zdravila splošni povzetek znanstvenega vrednotenja zdravil, vsebujočih piroksikam(glejte dodateki).

The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SPCs, labelling and package leaflets should be harmonised across the EU.
Ob upoštevanju predloženih podatkov in znanstvene razprave je CHMP menil, da je treba povzetke glavnih značilnosti zdravila, označevanje in navodilo za uporabo uskladiti v vsej EU.

The CHMP recommended the granting of the variation of the Marketing Authorisations for which the Summaries of Product Characteristics, Labelling and Package Leaflets are set out in Annex III and under the conditions set out in Annex IV.
Je CHMP priporočil odobritev spremembe dovoljenj za promet z zdravilom, katerega Povzetki glavnih značilnosti zdravila, Označevanje in Navodila za uporabo so navedeni v Dodatku III in pod pogoji, navedenimi v Dodatku IV.

The CHMP has recommended the maintenance of the Marketing Authorisations for the medicinal products referred to in Annex I for which the amendments to the relevant sections of the Summaries of Product Characteristics and Package Leaflets are set out in Annex III.
V skladu s tem je CHMP priporočil ohranitev dovoljenja za promet z zdravili, ki so navedena v Dodatku I in za katera so v Dodatku III podrobno predstavljene dopolnitve ustreznih točk v Povzetkih glavnih značilnosti zdravila in Navodilih za uporabo.

The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SPCs, labelling and package leaflets should be harmonised across the EU.
CHMP je ob upoštevanju predloženih podatkov in znanstvenih razprav v okviru Odbora menil, da je treba povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo uskladiti v celotni EU.

This Opinion recommended the maintenance of the Marketing Authorisations in accordance with the amendments to the relevant sections of the Summaries of Product Characteristics and Package Leaflets as set out in Annexes III and IV.
Mnenje je priporočilo vzdrževanje dovoljenj za promet v skladu z dopolnitvami ustreznih poglavij Povzetkov glavnih značilnosti zdravila in Navodil za uporabo, kot je navedeno v Dodatkih III in IV.

This has led to divergences across member states on the way the medicine can be used, as seen in the differences observed in the Summaries of Product Characteristics(SPCs), labelling and package leaflets in the countries where the product is marketed.
To je v državah članicah vodilo v razhajanja glede uporabe zdravila, kot je razvidno iz povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo v državah, v katerih je zdravilo na trgu.

This has led to divergences across member states on the way the medicine can be used, as seen in the differences observed in the Summaries of Product Characteristics(SPCs), labelling and package leaflets in the countries where the product is marketed.
To je privedlo do razhajanj med državami članicami glede načina uporabe zdravila, kar je razvidno iz razlik med povzetki glavnih značilnosti zdravila, označevanja in navodila za uporabo v državah, v katerih je zdravilo na trgu.

(a) veterinary medicinal products authorised within the Union by the Commission and by the competent authorities, together with their summaries of product characteristics, package leaflets and lists of sites where each product is manufactured;
(a) zdravilih za uporabo v veterinarski medicini, ki so jih Komisija in pristojni organi odobrili znotraj Unije, skupaj z njihovimi povzetki glavnih značilnosti in navodili za uporabo ter seznami obratov, kjer se vsako zdravilo proizvaja;

The general public shall have access to information in the product database as regards the list of the authorised veterinary medicinal products, their summaries of product characteristics, package leaflets and their environmental data, and all safety information.
Splošna javnost ima dostop do informacij v zbirki podatkov o zdravilih glede seznama odobrenih zdravil za uporabo v veterinarski medicini, njihovih povzetkov glavnih značilnosti, navodil za uporabo, njihovih podatkov o okolju ter vseh informacij o varnosti.